Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Therapeutics, Inc. filings document its OSA-focused medical device and healthcare services business, including reported operating results, sleep testing services, the integration of The Sleep Center of Nevada assets and treatment revenue from supported OSA care locations.
The company’s 8-K and related disclosures also cover material financing agreements, warrant exercises, private placements, convertible note terms, resale-registration references, board and committee appointments, annual-report timing and Nasdaq continued-listing compliance tied to stockholders’ equity. These filings describe common stock, warrants and other capital-structure instruments alongside governance and risk-related public-company matters.
Vivos Therapeutics, Inc. (VVOS) reported that director Leonard J. Sokolow received a grant of 12,000 stock options on September 14, 2026 at an exercise price of $0.18 per share, expiring September 14, 2036. One-half vested immediately, with one-fourth vesting on September 30, 2026 and one-fourth on December 31, 2026, bringing his directly held options to 17,600.
Vivos Therapeutics, Inc. (VVOS) reported that director Gregg C. Johnson received a grant of 12,000 stock options on September 14, 2026, each with an exercise price of $0.18 per share and a 10-year term. One-half of the options vested immediately, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026. After this grant, he holds 12,000 options directly and 3,997 shares of common stock indirectly through an affiliated limited partnership.
Vivos Therapeutics, Inc. (symbol: VVOS) is the issuer of record for a Form 4 filing submitted to the SEC.
Vivos Therapeutics, Inc. (VVOS) amended a prior current report to correct the transaction date and to restate details of a debt-for-equity exchange with Streeterville Capital, LLC. On September 2, 2026, Vivos issued 11,445,080 shares of common stock to Streeterville in exchange for secured promissory notes with an aggregate principal balance of $2,861,270.
The exchanges, effected through twelve partitioned notes under Section 3(a)(9) of the Securities Act, reduced the outstanding principal balance of the original Streeterville Note to $3.7 million. Common shares outstanding increased from 22,164,313 to 33,609,393, with the Exchange Shares representing approximately 52% of pre-transaction shares and 34% post-transaction shares, subject to a 4.9% Beneficial Ownership Limitation and a Sell-Down Condition.
Vivos Therapeutics, Inc. (VVOS) entered into twelve exchange agreements with Streeterville Capital, LLC on August 31, 2026 to retire $2,861,270 of principal from an existing secured promissory note by issuing up to 11,445,080 shares of common stock at an average exchange price of about $0.25 per share. These exchanges are structured so that each new note is surrendered and cancelled when the related shares become free trading, and are subject to a 4.9% Beneficial Ownership Limitation and a sell-down condition that restrict further exchanges until prior shares are sold.
Immediately before the exchanges, Vivos had 22,164,313 common shares outstanding; after settlement of all issuances, it will have 33,609,393 shares outstanding, with the Exchange Shares representing about 52% of pre-exchange shares and about 34% of post-exchange shares. Following these exchanges, the remaining outstanding principal balance of the Streeterville note is disclosed as $3.7 million, and Vivos receives no cash proceeds because this is a debt-for-equity exchange relying on the Section 3(a)(9) registration exemption.
Vivos Therapeutics, Inc. (VVOS) is reported to have 122,963 shares of its common stock beneficially owned by Streeterville Capital LLC, with Streeterville Management LLC and John M. Fife reporting indirect beneficial ownership. This position represents 0.6% of the common stock, based on 20,118,023 shares outstanding as of August 13, 2026. Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife each report sole voting and dispositive power over 122,963 shares and no shared voting or dispositive power. The reporting group states that it holds 5 percent or less of the class of VVOS common stock.
Vivos Therapeutics, Inc. (VVOS) reported that Principal Accounting Officer Bradford K. Amman received equity awards on July 31, 2026. He was granted 150,000 stock options with an exercise price of $0.41 per share, expiring July 31, 2036, and a separate grant of 250,000 shares of common stock at $0.41 per share. Following these grants, he holds 326,533 stock options and 250,080 shares of common stock directly. The option grant was made under the company’s 2024 Omnibus Equity Incentive Plan and is scheduled to vest at a stated rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.
Vivos Therapeutics, Inc. (VVOS) reported the grand opening of a new state-of-the-art sleep testing and treatment facility in Henderson, Nevada, as part of its Sleep Centers of Nevada network. The company expects this full-service center to more than double its annual revenue production capacity in Henderson to over $10 million.
At full capacity, the facility is expected to employ up to 30 personnel, including board-certified physicians, specialized dentists, nurse practitioners, and clinical staff, and to provide integrated diagnostics and treatments such as FDA-cleared oral appliance therapy and airway-focused dental sleep medicine. Management noted that incoming referrals in the Las Vegas market have more than doubled since the May–June timeframe, and expects the added capacity to have an immediate impact on revenue in that market. Vivos also highlights the large unmet need in sleep apnea care, including an estimated 200,000 Nevadans with undiagnosed sleep apnea and a global burden of about 1 billion adults with OSA and insomnia, most of whom remain undiagnosed.
Vivos Therapeutics, Inc. reports sharply higher revenue but deeper losses and mounting liquidity pressure for the three and six months ended June 30, 2026. Total revenue rose to $5.2M for the quarter and $10.3M year-to-date, up from $3.8M and $6.8M, driven mainly by growth in sleep testing services and new treatment center revenue tied to its pivot toward medical-provider alliances and the prior acquisition of The Sleep Center of Nevada.
Despite higher gross profit, operating expenses increased to $7.8M for the quarter and $17.5M year-to-date, producing an operating loss of $11.4M for the first half and a net loss attributable to stockholders of $13.2M. Cash used in operations was $9.2M in six months, leaving only $1.8M of cash against $28.1M of total liabilities and a stockholders’ deficit of $(3.8)M. Management explicitly states that these conditions and expected cash needs raise substantial doubt about the company’s ability to continue as a going concern and indicates reliance on continued equity and debt financing, including recent PIPE offerings, warrant exercises, ATM sales, and high-cost debt with original issue discounts, to fund operations and support Nasdaq listing compliance.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Vivos Therapeutics, Inc. common stock. They report beneficial ownership of 729,755 shares of common stock, representing 4.99% of the class. All 729,755 shares are subject to shared voting and dispositive power, with no sole voting or dispositive power reported.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement, and therefore may be deemed to beneficially own these securities. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these shares. The Master Fund disclaims beneficial ownership because it cannot vote or dispose of the securities under that agreement.